Cargando…

Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria

The Lower Austrian Wachau region was an early COVID-19 hotspot of infection. As previously reported, in June 2020, after the first peak of infections, we determined that 8.5% and 9.0% of the participants in Weißenkirchen and surrounding communities in the Wachau region were positive for immunoglobul...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebholz, Heike, Braun, Ralf J., Saha, Titas, Harzer, Oliver, Schneider, Miriam, Ladage, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328535/
https://www.ncbi.nlm.nih.gov/pubmed/35895668
http://dx.doi.org/10.1371/journal.pone.0271382
_version_ 1784757742446051328
author Rebholz, Heike
Braun, Ralf J.
Saha, Titas
Harzer, Oliver
Schneider, Miriam
Ladage, Dennis
author_facet Rebholz, Heike
Braun, Ralf J.
Saha, Titas
Harzer, Oliver
Schneider, Miriam
Ladage, Dennis
author_sort Rebholz, Heike
collection PubMed
description The Lower Austrian Wachau region was an early COVID-19 hotspot of infection. As previously reported, in June 2020, after the first peak of infections, we determined that 8.5% and 9.0% of the participants in Weißenkirchen and surrounding communities in the Wachau region were positive for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies against the receptor-binding domain of the spike protein of SARS-CoV-2, respectively. Here, we present novel data obtained eight months later (February 2021) from Weißenkirchen, after the second peak of infection, with 25.0% (138/552) and 23.6% (130/552) of participants that are positive for IgG and IgA, respectively. In participants with previous IgG/IgA positivity (June 2020), we observed a 24% reduction in IgG levels, whereas the IgA levels remained stable in February 2021. This subgroup was further analyzed for SARS-CoV-2 induced T cell activities. Although 76% (34/45) and 76% (34/45) of IgG positive and IgA positive participants, respectively, showed specific T cell activities (upon exposure to SARS-CoV-2 spike protein-derived peptides), those were not significantly correlated with the levels of IgG or IgA. Thus, the analyses of antibodies cannot surrogate the measurement of T cell activities. For a comprehensive view on SARS-CoV-2-triggered immune responses, the measurement of different classes of antibodies should be complemented with the determination of T cell activities.
format Online
Article
Text
id pubmed-9328535
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-93285352022-07-28 Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria Rebholz, Heike Braun, Ralf J. Saha, Titas Harzer, Oliver Schneider, Miriam Ladage, Dennis PLoS One Research Article The Lower Austrian Wachau region was an early COVID-19 hotspot of infection. As previously reported, in June 2020, after the first peak of infections, we determined that 8.5% and 9.0% of the participants in Weißenkirchen and surrounding communities in the Wachau region were positive for immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies against the receptor-binding domain of the spike protein of SARS-CoV-2, respectively. Here, we present novel data obtained eight months later (February 2021) from Weißenkirchen, after the second peak of infection, with 25.0% (138/552) and 23.6% (130/552) of participants that are positive for IgG and IgA, respectively. In participants with previous IgG/IgA positivity (June 2020), we observed a 24% reduction in IgG levels, whereas the IgA levels remained stable in February 2021. This subgroup was further analyzed for SARS-CoV-2 induced T cell activities. Although 76% (34/45) and 76% (34/45) of IgG positive and IgA positive participants, respectively, showed specific T cell activities (upon exposure to SARS-CoV-2 spike protein-derived peptides), those were not significantly correlated with the levels of IgG or IgA. Thus, the analyses of antibodies cannot surrogate the measurement of T cell activities. For a comprehensive view on SARS-CoV-2-triggered immune responses, the measurement of different classes of antibodies should be complemented with the determination of T cell activities. Public Library of Science 2022-07-27 /pmc/articles/PMC9328535/ /pubmed/35895668 http://dx.doi.org/10.1371/journal.pone.0271382 Text en © 2022 Rebholz et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rebholz, Heike
Braun, Ralf J.
Saha, Titas
Harzer, Oliver
Schneider, Miriam
Ladage, Dennis
Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria
title Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria
title_full Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria
title_fullStr Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria
title_full_unstemmed Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria
title_short Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria
title_sort longitudinal monitoring of sars-cov-2 spike protein-specific antibody responses in lower austria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328535/
https://www.ncbi.nlm.nih.gov/pubmed/35895668
http://dx.doi.org/10.1371/journal.pone.0271382
work_keys_str_mv AT rebholzheike longitudinalmonitoringofsarscov2spikeproteinspecificantibodyresponsesinloweraustria
AT braunralfj longitudinalmonitoringofsarscov2spikeproteinspecificantibodyresponsesinloweraustria
AT sahatitas longitudinalmonitoringofsarscov2spikeproteinspecificantibodyresponsesinloweraustria
AT harzeroliver longitudinalmonitoringofsarscov2spikeproteinspecificantibodyresponsesinloweraustria
AT schneidermiriam longitudinalmonitoringofsarscov2spikeproteinspecificantibodyresponsesinloweraustria
AT ladagedennis longitudinalmonitoringofsarscov2spikeproteinspecificantibodyresponsesinloweraustria